— Know what they know.
Not Investment Advice

EVO

Evotec SE
1W: +4.8% 1M: -32.2% 3M: -17.7% YTD: -23.9% 1Y: -33.0% 3Y: -73.3% 5Y: -85.8%
$2.38
-0.05 (-2.06%)
After Hours: $2.36 (-0.02, -0.84%)
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $845.9M · Alpha Radar Strong Sell · Power 35
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$845.9M
52W Range2.31-4.8
Volume82,944
Avg Volume137,962
Beta1.12
Dividend
Analyst Ratings
4 Buy 3 Hold 0 Sell
Consensus Buy
Company Info
CEOChristian Wojczewski
Employees4,766
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2004-02-05
Websiteevotec.com
Essener Bogen 7
Hamburg 22419
DE
49 40 560 81 0
About Evotec SE

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Recent Insider Trades

NameTypeSharesPriceDate
Anderson Mark Monroe A-Award 100,000 $2.50 2018-10-22
Anderson Mark Monroe 0 2018-10-22
QUINTON KEITH 0 2018-10-01
Smith Marcus L. 0 2018-10-01
Smith Scott Clifford A-Award 100,000 $2.50 2018-08-13

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms